Logo image of MDWD

MEDIWOUND LTD (MDWD) Stock Fundamental Analysis

NASDAQ:MDWD - IL0011316309 - Common Stock

19.06 USD
+0.61 (+3.31%)
Last: 9/11/2025, 8:00:01 PM
19.06 USD
0 (0%)
After Hours: 9/11/2025, 8:00:01 PM
Fundamental Rating

2

MDWD gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of MDWD have multiple concerns. MDWD is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MDWD has reported negative net income.
In the past year MDWD has reported a negative cash flow from operations.
MDWD had negative earnings in each of the past 5 years.
In the past 5 years MDWD always reported negative operating cash flow.
MDWD Yearly Net Income VS EBIT VS OCF VS FCFMDWD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

MDWD's Return On Assets of -41.72% is in line compared to the rest of the industry. MDWD outperforms 42.56% of its industry peers.
MDWD has a Return On Equity of -138.93%. This is in the lower half of the industry: MDWD underperforms 65.13% of its industry peers.
Industry RankSector Rank
ROA -41.72%
ROE -138.93%
ROIC N/A
ROA(3y)-30.14%
ROA(5y)-37.73%
ROE(3y)-99.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MDWD Yearly ROA, ROE, ROICMDWD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 -200

1.3 Margins

The Gross Margin of MDWD (18.43%) is comparable to the rest of the industry.
MDWD's Gross Margin has declined in the last couple of years.
MDWD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 18.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-29.33%
GM growth 5Y-26.97%
MDWD Yearly Profit, Operating, Gross MarginsMDWD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

2

2. Health

2.1 Basic Checks

MDWD does not have a ROIC to compare to the WACC, probably because it is not profitable.
MDWD has more shares outstanding than it did 1 year ago.
MDWD has more shares outstanding than it did 5 years ago.
The debt/assets ratio for MDWD has been reduced compared to a year ago.
MDWD Yearly Shares OutstandingMDWD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
MDWD Yearly Total Debt VS Total AssetsMDWD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

MDWD has a Debt/Equity ratio of 0.40. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.40, MDWD is in line with its industry, outperforming 42.05% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC8.66%
MDWD Yearly LT Debt VS Equity VS FCFMDWD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M 30M

2.3 Liquidity

A Current Ratio of 1.48 indicates that MDWD should not have too much problems paying its short term obligations.
MDWD has a worse Current ratio (1.48) than 68.72% of its industry peers.
MDWD has a Quick Ratio of 1.35. This is a normal value and indicates that MDWD is financially healthy and should not expect problems in meeting its short term obligations.
MDWD has a worse Quick ratio (1.35) than 65.13% of its industry peers.
Industry RankSector Rank
Current Ratio 1.48
Quick Ratio 1.35
MDWD Yearly Current Assets VS Current LiabilitesMDWD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

4

3. Growth

3.1 Past

MDWD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -22.22%.
The Revenue has decreased by -1.42% in the past year.
The Revenue has been decreasing by -8.65% on average over the past years.
EPS 1Y (TTM)-22.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80.88%
Revenue 1Y (TTM)-1.42%
Revenue growth 3Y-5.23%
Revenue growth 5Y-8.65%
Sales Q2Q%12.74%

3.2 Future

The Earnings Per Share is expected to grow by 18.12% on average over the next years. This is quite good.
MDWD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 41.51% yearly.
EPS Next Y24.52%
EPS Next 2Y9.64%
EPS Next 3Y9.96%
EPS Next 5Y18.12%
Revenue Next Year18.48%
Revenue Next 2Y22.14%
Revenue Next 3Y19.9%
Revenue Next 5Y41.51%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MDWD Yearly Revenue VS EstimatesMDWD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M 200M 250M
MDWD Yearly EPS VS EstimatesMDWD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 -4 6 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MDWD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDWD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDWD Price Earnings VS Forward Price EarningsMDWD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDWD Per share dataMDWD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.64%
EPS Next 3Y9.96%

More info and screens

0

5. Dividend

5.1 Amount

MDWD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEDIWOUND LTD

NASDAQ:MDWD (9/11/2025, 8:00:01 PM)

After market: 19.06 0 (0%)

19.06

+0.61 (+3.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-24 2025-11-24
Inst Owners35.7%
Inst Owner Change-5.29%
Ins Owners1.68%
Ins Owner ChangeN/A
Market Cap207.37M
Analysts83.33
Price Target31.28 (64.11%)
Short Float %9.94%
Short Ratio10.78
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.66%
Min EPS beat(2)-110.94%
Max EPS beat(2)89.63%
EPS beat(4)2
Avg EPS beat(4)-24.03%
Min EPS beat(4)-116.72%
Max EPS beat(4)89.63%
EPS beat(8)4
Avg EPS beat(8)-30.38%
EPS beat(12)5
Avg EPS beat(12)-23.64%
EPS beat(16)7
Avg EPS beat(16)-18.97%
Revenue beat(2)0
Avg Revenue beat(2)-13.42%
Min Revenue beat(2)-25.41%
Max Revenue beat(2)-1.43%
Revenue beat(4)0
Avg Revenue beat(4)-14.04%
Min Revenue beat(4)-28.91%
Max Revenue beat(4)-0.39%
Revenue beat(8)1
Avg Revenue beat(8)-7.1%
Revenue beat(12)4
Avg Revenue beat(12)1.97%
Revenue beat(16)6
Avg Revenue beat(16)1.17%
PT rev (1m)0%
PT rev (3m)2.22%
EPS NQ rev (1m)-23.92%
EPS NQ rev (3m)-22.06%
EPS NY rev (1m)-8.78%
EPS NY rev (3m)20.29%
Revenue NQ rev (1m)-1.5%
Revenue NQ rev (3m)-0.84%
Revenue NY rev (1m)-0.23%
Revenue NY rev (3m)-2.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.44
P/FCF N/A
P/OCF N/A
P/B 10.31
P/tB 10.34
EV/EBITDA N/A
EPS(TTM)-2.64
EYN/A
EPS(NY)-2.45
Fwd EYN/A
FCF(TTM)-1.77
FCFYN/A
OCF(TTM)-1.4
OCFYN/A
SpS1.83
BVpS1.85
TBVpS1.84
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.72%
ROE -138.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 18.43%
FCFM N/A
ROA(3y)-30.14%
ROA(5y)-37.73%
ROE(3y)-99.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-29.33%
GM growth 5Y-26.97%
F-Score2
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 265.85%
Cap/Sales 20.15%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.48
Quick Ratio 1.35
Altman-Z N/A
F-Score2
WACC8.66%
ROIC/WACCN/A
Cap/Depr(3y)321.06%
Cap/Depr(5y)217.42%
Cap/Sales(3y)22.58%
Cap/Sales(5y)14.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-22.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80.88%
EPS Next Y24.52%
EPS Next 2Y9.64%
EPS Next 3Y9.96%
EPS Next 5Y18.12%
Revenue 1Y (TTM)-1.42%
Revenue growth 3Y-5.23%
Revenue growth 5Y-8.65%
Sales Q2Q%12.74%
Revenue Next Year18.48%
Revenue Next 2Y22.14%
Revenue Next 3Y19.9%
Revenue Next 5Y41.51%
EBIT growth 1Y-46.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2.62%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-92.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-112.83%
OCF growth 3YN/A
OCF growth 5YN/A